Verastem Inc logo

Verastem Inc

1
FRA:2VSA (USA)  
€ 3.04 (+1.33%) Jun 20
At Loss
P/B:
3.28
Market Cap:
€ 76.59M ($ 81.90M)
Enterprise V:
€ 33.15M ($ 35.45M)
Volume:
-
Avg Vol (2M):
3.25K
Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Verastem Inc ( ) from 2012 to Jun 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Verastem stock (FRA:2VSA) PE ratio as of Jun 21 2024 is 0. More Details

Verastem Inc (FRA:2VSA) PE Ratio (TTM) Chart

To

Verastem Inc (FRA:2VSA) PE Ratio (TTM) Historical Data

Total 1290
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Verastem PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-22 At Loss 2024-04-18 At Loss
2024-06-20 At Loss 2024-04-17 At Loss
2024-06-19 At Loss 2024-04-16 At Loss
2024-06-18 At Loss 2024-04-15 At Loss
2024-06-17 At Loss 2024-04-12 At Loss
2024-06-14 At Loss 2024-04-11 At Loss
2024-06-13 At Loss 2024-04-10 At Loss
2024-06-12 At Loss 2024-04-09 At Loss
2024-06-11 At Loss 2024-04-08 At Loss
2024-06-10 At Loss 2024-04-05 At Loss
2024-06-07 At Loss 2024-04-04 At Loss
2024-06-06 At Loss 2024-04-03 At Loss
2024-06-05 At Loss 2024-04-02 At Loss
2024-06-04 At Loss 2024-03-28 At Loss
2024-06-03 At Loss 2024-03-27 At Loss
2024-05-31 At Loss 2024-03-26 At Loss
2024-05-30 At Loss 2024-03-25 At Loss
2024-05-29 At Loss 2024-03-22 At Loss
2024-05-28 At Loss 2024-03-21 At Loss
2024-05-27 At Loss 2024-03-20 At Loss
2024-05-24 At Loss 2024-03-19 At Loss
2024-05-23 At Loss 2024-03-18 At Loss
2024-05-22 At Loss 2024-03-15 At Loss
2024-05-21 At Loss 2024-03-14 At Loss
2024-05-20 At Loss 2024-03-13 At Loss
2024-05-17 At Loss 2024-03-12 At Loss
2024-05-16 At Loss 2024-03-11 At Loss
2024-05-15 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-03-01 At Loss
2024-05-07 At Loss 2024-02-29 At Loss
2024-05-06 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss

Verastem Inc (FRA:2VSA) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.